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Abstract
The cingulate island sign (CIS) refers to the relative sparing of
metabolism in the posterior cingulate cortex (PCC) and represents
an important biomarker in distinguishing dementia with Lewy bod-
ies (DLB) from Alzheimer disease (AD). The underlying basis of
the CIS is unknown; therefore, our aim was to investigate which
neurodegenerative changes underpin the formation of CIS. Using
quantitative neuropathology, a-synuclein, phosphorylated Tau, and
amyloid-b pathology was assessed in 12 DLB, 9 AD and 6 age-
matched control patients in the anterior cingulate (ACC), midcingu-
late, PCC, precuneus/cuneus and parahippocampal gyrus. All
participants had undergone 99mTc-hexamethylpropyleneamine ox-
ime (HMPAO) single-photon emission computed tomography imag-
ing during life to define the presence or absence of CIS. In the DLB
group, no significant correlations were observed between CIS ratios
and neurodegenerative pathology in PCC. In DLB, however, the
ACC showed lower HMPAO uptake, as well as significantly higher
a-synuclein and amyloid-b burden compared with PCC, possibly un-
derlying the relative preservation of perfusion in PCC when com-
pared with ACC. Our findings suggest that neurodegenerative
pathology does not directly correlate with the CIS in DLB, and other
metabolic or pathological changes are therefore more likely to be
relevant for the development of the CIS.
Key Words: a-Synuclein, Alzheimer disease, Cingulate island sign,
Dementia with Lewy bodies, Single-photon emission tomography
(SPECT).
INTRODUCTION
Dementia with Lewy bodies (DLB) is second only to
Alzheimer disease (AD) in terms of prevalence, accounting
for 15%–20% of all neuropathologically defined dementia
patients (1). Clinically DLB is characterized by progressive
dementia, parkinsonism, fluctuating cognition, recurrent com-
plex visual hallucinations, and rapid eye movement sleep be-
havior disorder (2). Early and accurate diagnosis of DLB is
essential for optimal management of the disorder (2–4). Sev-
eral biomarkers are used clinically in the differential diagnosis
of DLB, with dopamine transporter imaging proven to be ef-
fective in detecting early nigrostriatal changes (5, 6) and
[123I]metaiodobenzylguanidine myocardial scintigraphy to de-
tect changes in the peripheral sympathetic nervous system (7).
The cingulate island sign (CIS) is a supportive biomarker in
discriminating DLB from AD according to diagnostic criteria
(2, 8, 9), and refers to the relative preservation of posterior cin-
gulate cortex (PCC) metabolism, in relation to precuneus and
cuneus (Pr/Cu) metabolism, and is commonly observed in
DLB patients (10, 11). This can be identified using 18F-fluoro-
deoxyglucose (FDG) positron-emission tomography (PET)
imaging and also using hexamethylpropyleneamine oxime
(HMPAO) single-photon emission computed tomography
(SPECT) as a marker of perfusion to define the CIS (12).
A pathological hallmark of DLB is aggregation of a-syn-
uclein protein, the major component of Lewy bodies and Lewy
neurites found in widespread cortical and subcortical brain
regions (13). Neuropathological characteristics of AD are de-
fined by the presence of extracellular aggregation of amyloid-
beta (Ab) protein in the form of senile plaques and perivascular
amyloid, as well as neurofibrillary tangles (NFT) and neuropil
threads, composed of hyperphosphorylated microtubule associ-
ated protein Tau (p-Tau). DLB and AD patients share many
clinical and pathological characteristics, with some coexisting
AD pathology observed in 50%–80% of pathologically con-
firmed DLB patients (14). Clinico-pathological correlation has
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been able to demonstrate that biomarkers of DLB, such as re-
duced dopamine transporter uptake in the striatum is due to
pathological change in the midbrain substantia nigra (15). Sim-
ilarly, reduced cardiac [123I]metaiodobenzylguanidine uptake
in DLB may have as its basis decreased cardiac sympathetic in-
nervation due to degeneration of noradrenergic nerve fibers
(16). How pathology affects the presence of a specific bio-
marker such as CIS is therefore a key question in determining
the validity of a biomarker.
The semiquantitative scoring of pathology using NFT
Braak staging has been suggested to be a correlate of the CIS
using FDG-PET (10), with CIS in DLB thought to be reflec-
tive of lower p-Tau pathological burden, although the intrinsic
pathological basis of the CIS is unknown. While FDG-PET
imaging has been shown to be more sensitive in detecting CIS
(12), SPECT imaging is more widely used for clinical screen-
ing and examination of patients with dementia (17), with high
sensitivity in detecting differences in cerebral perfusion be-
tween AD and DLB (8, 17). We therefore determined how dif-
ferent cingulate pathologies relate to CIS assessed using
Technetium-99m (99mTc)-HMPAO SPECT imaging in a co-
hort of clinically and pathologically characterized group of
older individuals.
MATERIALS ANDMETHODS
Cohort
Patients and control donors were part of longitudinal
studies undertaken at Newcastle University. Ethical approval
for the study was granted by the Newcastle and North Tyne-
side National Health Service (NHS) Research Ethics Commit-
tee. All patients had received physical, neurological and
neuropsychiatric examinations during life. All patients had
consented to the use of their brain tissue for research purposes
and next of kin gave consent to donate after death. Postmortem
neuropathological assessment was performed according to
standardized neuropathological diagnostic procedures, which
together with clinical data was used to make a clinicopatho-
logical diagnosis (2). Brain tissue was obtained from the New-
castle Brain Tissue Resource (NBTR), a UK Human Tissue
Authority-regulated research tissue bank.
Patients were diagnosed in life as having DLB (n¼ 12),
AD (n¼ 9) or were neurologically and psychiatrically normal
(n¼ 6). Standardized neuropathological assessment was
according to internationally accepted criteria (1, 18, 19). Of
note, 4 DLB patients also fulfilled the neuropathological criteria
for high AD neuropathological change and could therefore be
classified as neuropathologically mixed AD/DLB with a Lewy
body disease (LBD) clinical phenotype (20, 21). All patients
had undergone 99mTc-hexamethylpropyleneamine oxime
(99mTc-HMPAO) SPECT scans during life. 99mTc-HMPAO is
a radioactive tracer which is injected intravenously, taken up in
the brain in proportion to cerebral perfusion, and the pattern of
its distribution is determined with SPECT imaging with a spa-
tial resolution of 10 mm (Fig. 1). Ten individuals with DLB
(3 of which were mixed AD/DLB patients), 8 AD and 6 normal
controls also had magnetic resonance imaging (MRI) scans,
with cortical thickness and volumes taken from the nearest
MRI to death. 99mTc-HMPAO SPECT and MRI scans were
obtained from previously published studies (22–24). The Mini-
Mental State Examination (MMSE), Unified Parkinson’s Dis-
ease Rating Scale (UPDRS) scores and duration of illness were
recorded at the time of SPECT. Cerebral perfusion and MRI
volume data were acquired for the anterior cingulate cortex
(ACC), midcingulate cortex (MCC), PCC, precuneus/cuneus
(Pr/Cu), and parahippocampal gyrus (PHG).
Postmortem Tissue Samples
At autopsy, the right hemisphere was fixed in 10% for-
malin for 4–6 weeks. Following fixation, the hemisphere was
cut into 7-mm coronal slices then dissected into blocks and
FIGURE 1. 99mTc-HMPAO SPECT perfusion images from
control, Alzheimer disease, and dementia with Lewy bodies
donors. Representative axial slice images (A, C, E) through
the posterior cingulate and (B, D, F) midline sagittal slice
images of perfusion determined using 99mTc-HMPAO SPECT.
In older normal patients (A, B) without dementia, the
posterior cingulate cortex (arrow) and precuneus (asterisk)
appear relatively bright. In AD patients (C, D), perfusion
intensity is reduced in both these structures. In DLB patients
(E, F), the precuneus shows a greater reduction compared
with the posterior cingulate cortex, which shows relatively
preserved perfusion. (L, left; R, right; A, anterior; P, posterior;
S, superior; I, inferior.)
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embedded in paraffin wax for neuropathological assessment.
Paraffin embedded tissue blocks selected for analysis corre-
sponded to ACC (Brodmann area: BA 24, at the level of the
genu of the corpus callosum), MCC (BA 240, coronal level of
the primary motor cortex), PCC (BA 23, coronal level of the
splenium of the corpus callosum), precuneus (BA 40, coronal
level of supramarginal gyrus), and PHG (BA 28, coronal level
of lateral geniculate nucleus) (25). For a-synuclein the ethyle-
nediamine tetra-acetic acid (EDTA) heat-induced antigen re-
trieval pH 8.0 was performed in a pressure cooker for
2 minutes, followed by 15 minutes in absolute formic acid at
room temperature. The citrate heat-induced antigen retrieval
pH 6.0 for 10 minutes at full power in an 800 W microwave
was carried out for p-Tau, whereas 1 hour formic acid antigen
retrieval for Ab. Ten-micrometer sections (1 per region of in-
terest) were immunostained with primary antibodies to a-syn-
uclein (KM51 anti-a-synuclein, Leica Biosystems, Buffalo
Grove, IL, 1:250), p-Tau (AT8 antiphosphorylated tau, Auto-
gen, Holliston, MA, 1:4000), and Ab (4G8 anti-amyloid-b
peptide, Covance, Princeton, NJ, 1:15 000). Immunolabeling
was detected using the Menarini X-Cell-Plus HRP Detection
Kit (Menarini, Wokingham, UK) and visualized using diami-
nobenzidine (Menarini) substrate. Neuronal cell number
within the regions of interest was assessed using 3 10-mm sec-
tions stained with Cresyl fast violet (26).
Neuropathological Image Analysis
For quantification of neuropathological lesions, the
images were captured using a Zeiss Z1 microscope and MRc
camera (Zeiss, Oberkochen, Germany) coupled to a PC with a
motorized stage. The regions of interest were drawn at 1.25
magnification from the pial surface and using a line perpendic-
ular to the white matter to encompass the immediate subjacent
white matter, thereby covering all of the cortical gray matter
within the region. Dissector boxes were placed in a uniform
and unbiased way within the region of interest, with 10–15
frames captured at 10 magnification per region of interest
for densitometric analysis. The images were analyzed using
ImageJ 1.48v analysis software (Java 1.6.0_20 [64-bit]: http://
imagej.nih.gov/ij, accessed May 29, 2019). The mean percent-
age area stained for each frame was determined using the red-
green-blue (RGB) thresholds, which were optimized manually
for each antibody to eliminate the detection of any nonspecific
background staining, with thresholds set at a level that was
reached by immunopositive pathological structures only. The
mean percentage area stained per case was calculated from the
mean values obtained across all images taken. For Cresyl fast
violet-stained sections the same regions of interest were used
as for quantification of neuropathological lesions, with the
images captured using 63x oil immersion objective (26).
Three 10-lm sections were used for each case to ensure ade-
quate sampling. Differentiation of neuronal cells from glia
was based on standard morphological criteria (27, 28). We
used a systematic approach that employed an adaptation of
stereology software to enable cell counts within a specified
area, which was defined at 1.25 magnification, with 20–30
dissector frames randomly placed within the region of interest.
The number of frames used was determined on the basis of the
pilot study, generating sufficiently low coefficient of error. A
systematic, randomly oriented point grid was superimposed
over each image, with neurons counted within a dissector
frame of known dimensions, generating an estimated neuronal
number (mm2).
SPECT Image Analysis
As previously described (24), each image volume was
registered to standard MNI (Montreal Neurological Institute,
http://www.bic.mni.mcgill.ca) space using statistical para-
metric mapping (SPM2, Wellcome Department of Imaging
Neuroscience, London, UK, http://www.fil.ion.ucl.ac.uk/
spm). Mean intensities representing relative perfusion within
standard regions of interest were then calculated for each
scan using the marsbar SPM toolbox (http://marsbar.source-
forge.net/) (29). Regions included the PHG, precuneus,
cuneus, ACC, MCC, and PCC from the Desikan atlas (30) in
freesurfer. These regions were smoothed by 8 mm FWHM
Gaussian and thresholded to match the resolution of the
SPECT. Intensities are presented relative to whole brain up-
take. Data were taken from the right hemisphere only to
match the postmortem data. The mean intensities for perfu-
sion in the SPM2-defined regions of interest were used
whereby the mean perfusion values for PCC were divided
by the mean values in the Pr/Cu to derive the CIS ratio from
the 99mTc-HMPAO SPECT perfusion data similar to the ap-
proach used previously (10, 17).
MRI Image Analysis
Volumetric estimates (mm3) of the cingulate substruc-
tures (i.e. ACC, MCC, and PCC) were then derived for each
individual from data obtained from cortical reconstructions/
segmentation of MRI scans using the FreeSurfer image analy-
sis suite (v 5.1, http://surfer.nmr.mgh.harvard.edu/), the tech-
nical details of which have been described in prior reports
(30–32).
Statistical Analysis
Statistical analysis was undertaken in SPSS Statistics
version 23.0. Distributional assumptions for outcome meas-
ures were assessed using the Shapiro–Wilk test. The nonpara-
metric tests were applied for the neuropathological data
analysis, as it did not meet the normal distribution criteria.
The differences between multiple disease groups were
assessed using Kruskal–Wallis test, and Friedman’s ANOVA
for paired analysis. The effect sizes for group differences were
assessed using Wilcoxon test. Correlation analyses were car-
ried out using Spearman’s correlation coefficient rho. The re-
lationship between CIS ratios, pathological, clinical and
densitometric variables were assessed using linear regression
analyses. Group comparisons within the regions of interest for
cerebral perfusion, volumetric and densitometric data were
carried out using analysis of variance (ANOVA), with
reported p values adjusted for multiple comparisons using
Bonferroni posthoc test.
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RESULTS
Pathology
No significant difference was found in the gender
(p¼ 0.701), age at diagnosis (p¼ 0.200), and postmortem de-
lay (p¼ 0.413) between the groups. A significant difference
was observed in the age at death between groups, with DLB
patients showing significantly younger age at death compared
with controls (p¼ 0.012) and AD (p¼ 0.030; Supplementary
Data Table S1).
Alpha-synuclein pathology was significantly higher in
DLB patients compared with controls and AD in ACC, MCC,
PCC, Pr/Cu, and PHG (p< 0.001; Fig. 2A). DLB patients
showed significantly different a-synuclein burden distribu-
tions between cingulate subregions (v2(2)¼ 6.000, p¼ 0.050),
with significantly higher a-synuclein burden observed in ACC
compared with PCC (p¼ 0.043). No significant differences
were observed in a-synuclein burden between cingulate subre-
gions in controls and AD (Supplementary Data Fig. S1).
Phosphorylated Tau pathological burden was signifi-
cantly different in ACC (H(2)¼ 8.766, p¼ 0.012), MCC
(H(2)¼ 8.635, p¼ 0.013), and Pr/Cu (H(3)¼ 9.863,
p¼ 0.007) across disease groups. AD patients showed signifi-
cantly higher p-Tau burden compared with DLB in Pr/Cu
(p¼ 0.010), and compared with controls in ACC and MCC
(p¼ 0.010; Fig. 2B). NFT Braak stage was significantly
higher in AD patients compared with controls and DLB
(p< 0.001; Supplementary Data Table S1). No significant dif-
ference was observed in cingulate regional p-Tau pathology
distribution within DLB, AD, or control groups (Supplemen-
tary Data Fig. S2).
Amyloid-b pathological burden was significantly differ-
ent in ACC, MCC, PCC, and Pr/Cu across disease groups. AD
patients showed significantly higher Ab burden compared
with DLB in ACC (p¼ 0.046), MCC (p¼ 0.025), PCC
(p¼ 0.015), and Pr/Cu (p¼ 0.008), as well as compared with
controls in Pr/Cu (p¼ 0.017; Fig. 2C). DLB patients showed
significantly different Ab burden distribution between cingu-
late subregions (v2(2)¼ 8.667, p¼ 0.013), with significantly
higher Ab burden observed in ACC compared with MCC
(p¼ 0.013). No significant changes were observed in cingu-
late regional Ab pathology distribution within AD or control
groups (Supplementary Data Fig. S3).
Neuronal density (neurons per mm2) was significantly
higher in controls compared with AD in ACC (p¼ 0.011) and
PHG (p¼ 0.003), and in controls compared with DLB in PHG
(p¼ 0.010). Significantly higher neuronal numbers were also
observed in MCC in DLB compared with AD (p¼ 0.025;
Fig. 2D). In DLB group the cell density was significantly
greater in PCC compared with ACC (p¼ 0.043).
Imaging
No significant difference was observed in the disease
duration at the time of SPECT (p¼ 0.592) between DLB and
AD. MMSE scores at the time of SPECT were significantly
higher in controls compared with DLB (p¼ 0.003) and AD
(p¼ 0.005), whereas UPDRS scores were significantly higher
in DLB patients compared with controls (p¼ 0.006) and AD
(p¼ 0.012). The interval between SPECT and death was sig-
nificantly longer in controls (p¼ 0.001) and AD patients
(p¼ 0.046) compared with DLB (Supplementary Data Table
S1). 99mTc-HMPAO SPECT uptake was not significantly dif-
ferent in any regions of interest between the groups (Table).
Paired analysis within the DLB group showed significantly
higher 99mTc-HMPAO SPECT uptake in PCC (p¼ 0.045) and
MCC (p¼ 0.006) compared with ACC. 99mTc-HMPAO
SPECT uptake in the AD group was also significantly higher
in MCC (p¼ 0.012), but not PCC (p¼ 0.148) compared with
ACC. No significant difference in 99mTc-HMPAO SPECT up-
take between cingulate subregions was observed in control
patients. MRI volumes were significantly different in PCC be-
tween groups (F(2, 21)¼ 6.172, p¼ 0.008), with significantly
higher PCC volume observed in controls compared with AD
(p¼ 0.009; Table). The CIS ratios were significantly higher in
DLB patients compared with AD (p¼ 0.041; Fig. 3).
Linear Regression Analyses
No significant correlations were observed between a-
synuclein, p-Tau or Ab pathology in PCC and Pr/Cu with CIS
ratios, or 99mTc-HMPAO SPECT uptake in PCC or Pr/Cu
within DLB group. Furthermore, no significant correlation
was observed between CIS ratios, 99mTc-HMPAO SPECT up-
take in PCC, or Pr/Cu with NFT Braak stage in the DLB
group. The neurodegenerative pathology in PCC also did not
show significant correlations between cell density and volume
in PCC in DLB. Additionally, we saw no correlations between
MMSE scores at the time of SPECT with CIS ratios, or disease
duration at the time of SPECT in DLB (Supplementary Data
Fig. S4).
DISCUSSION
The CIS is a supportive biomarker showing high sensi-
tivity and specificity in differentiating DLB from AD (2), and
has been suggested to be indicative of the lower NFT Braak
stage in patients with DLB using FDG-PET (10), although the
underlying pathological basis of the CIS is unknown. In this
study we observed significantly higher CIS ratios in DLB
compared with AD using 99mTc-HMPAO SPECT, in line with
previous FDG-PET studies (9, 12). Our findings indicate that
the currently considered classic pathological indicators of neu-
rodegeneration did not correlate with the preserved metabo-
lism of the PCC in DLB.
Unsurprisingly, DLB patients had higher a-synuclein
burden in all cingulate regions compared with AD and con-
trols. Within the DLB group a significantly higher a-synuclein
burden was observed in ACC compared with PCC. Similar to
previous studies (33–36), we also observed reduced metabolic
activity in the ACC in DLB patients compared with MCC and
PCC (Table), suggesting relatively preserved perfusion in
PCC—the basis of the CIS. We, however, did not observe sig-
nificant correlations between levels of a-synuclein pathology
in PCC with CIS or 99mTc-HMPAO SPECT uptake in PCC.
This suggests that it is the relative levels of a-synuclein pa-
thology between ACC and PCC that relate to the metabolic
differences that give the CIS—high levels of a-synuclein in
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ACC leading to lower metabolism relative to lower levels of
a-synuclein pathology in the PCC and preserved metabolism.
The lack of a direct relationship between pathology may indi-
cate that there is a threshold effect, once certain levels of pa-
thology are reached, metabolism begins to decline and
metabolic imaging changes can be observed. More direct
markers of metabolism that are downstream consequences of
pathological change will be required to observe these meta-
bolic changes and allow the relationships between pathology
and metabolism to be explored.
AD patients had significantly higher p-Tau burden com-
pared with controls in ACC and MCC, and compared with
DLB in Pr/Cu. While other studies have observed a relation-
ship between lower NFT Braak stage and higher CIS ratios in
clinically diagnosed DLB patients (10, 37), we found no such
correlation. We also failed to observe a relationship between
tau pathological burden in PCC with CIS and perfusion in
PCC. The CIS is not specific to DLB and has been shown to
be present in posterior cortical atrophy (PCA) (38). A high
NFT Braak stage is typically observed in PCA (39), which
may reflect differential AD pathology distribution (40) and
potentially supports our finding of no association between
NFT pathology and the CIS.
While it is unclear how the patterns of hypometabolism
in dementia relate to underlying neuropathology, it has been
suggested that Ab deposition in posterior cortical regions may
result in reduced metabolic activity in AD (41). Ab burden
was significantly higher in AD patients in all cingulate subre-
gions and Pr/Cu compared with DLB. No correlations between
Ab burden in PCC and CIS ratio or 99mTc-HMPAO SPECT
FIGURE 2. Pathological and cell number changes in cingulate subregions, precuneus/cuneus and parahippocampal gyrus in
older normal, dementia with Lewy bodies (DLB), and Alzheimer disease (AD) donors. Postmortem brain tissue from DLB, AD, and
control donors was sampled in specific brain regions associated with the cingulate island sign and 10-lm-thick tissue sections
immunohistochemically stained to demonstrate neurodegenerative pathology, or stained using standard cresyl fast violet stain to
demonstrate cellular morphology. Pathological burden (% area stained) was determined using computer-aided image analysis of
(A) a-synuclein; (B) phosphorylated Tau (p-Tau); (C) amyloid-b (Ab); and a stereological approach used to determine (D)
neuronal number (mm2) in anterior cingulate cortex (ACC), midcingulate cortex (MCC), posterior cingulate cortex (PCC),
precuneus/cuneus (Pr/Cu), and parahippocampal gyrus (PHG). Bars represent mean and SD (controls n¼6; DLB n¼12; and AD
n¼9). a-Synuclein was significantly higher in DLB in all regions studied compared with both AD and control groups (A).
Phosphorylated tau burden was significantly higher in AD compared with controls in ACC and MCC (B). Ab burden was also
higher in AD compared with DLB in all cingulate regions but did not differ from controls (C), whereas cell count in AD ACC was
reduced compared with control and in MCC compared with DLB (significance levels set at *p<0.05, **p<0.01, and
***p<0.001). Box plots represent the median (midline) and quartile ranges, with error bars representing the minimum and
maximum values.
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uptake in PCC have been observed, which may suggest that
Ab pathology does not contribute directly to the reduced meta-
bolic activity in the PCC.
While some studies have suggested that posterior corti-
cal hypometabolism may be driven by cell loss, as observed in
AD patients (37), we did not observe a relationship between
CIS ratio and cell density. Occipital hypometabolism is also a
common feature in DLB (11, 24). This region does not show
significant atrophy (42), and typically does not show major
pathological changes (43), which may suggest that factors
other than pathological burden, cell loss or atrophy play a role
in reduced metabolism in specific brain structures. Since the
CIS is a metabolic marker, direct determination of underlying
changes in metabolism in tissue may be more suitable.
Markers such as mitochondrial enzymes or structural proteins
are indicators of metabolic activity and may represent direct
indicators of HMPAO retention. Similarly, synaptic activity is
closely correlated with metabolism (44) and specific synaptic
markers may provide suitable pathological markers of perfu-
sion given the known loss of synapses in neurodegenerative
disorders (45). Further work using such markers is therefore
warranted to identify the basis of the CIS.
Hippocampal atrophy and PCC hypometabolism are
common features of AD (23, 24). The hypometabolism of the
PCC in AD and also lateral parietal cortex is thought to reflect
disrupted inputs from the hippocampus (23, 46). While some
studies have shown hippocampal atrophy to be associated with
white matter changes in the cingulum in AD (47, 48), other
studies have found that global rather than hippocampal atro-
phy correlated with white matter changes (23). The PCC is
part of the default mode network and has high metabolic
demands, which may suggest it has a higher vulnerability to
damage. Whether the disruption of the cingulum precedes or
is consequent upon hippocampal atrophy or PCC hypometabo-
lism is not clear. A recent study has observed temporal
changes in the CIS, with CIS in DLB being present at early
disease stages and CIS diminishing with disease progression
(49), however, we did not observe a relationship between CIS
and MMSE scores, or disease duration at the time of SPECT.
In the current study, we saw no significant changes in perfu-
sion between groups in the regions of interest (Table). This is
similar to previous work, which demonstrated significant
changes in perfusion generally in frontal and temporal regions
in AD, and in frontal and occipital regions in DLB compared
with older control individuals (24). In DLB there was a trend
toward reduction in perfusion (p¼ 0.057) in the Pr/Cu in line
with other studies (24) and similarly in AD a trend toward re-
duced perfusion in the PCC (p¼ 0.158), although much larger
groups sizes would be required to show this definitively. At an
individual level the CIS, which depends on the ratio of PCC
FIGURE 3. 99mTc-HMPAO SPECT derived cingulate island sign
(CIS) ratio in older normal, dementia with Lewy bodies (DLB),
and Alzheimer disease (AD) donors. 99mTc-HMPAO SPECT
imaging was performed in DLB (n¼12), AD (n¼9) patients or
controls (n¼6) and images used to derive CIS values based on
the ratio of posterior cingulate cortex (PCC) to precuneus/
cuneus (Pr/Cu) perfusion values. Box plots of the CIS ratio
represent the median (midline) and quartile ranges, with error
bars representing the minimum and maximum values. DLB
patients showed higher CIS ratio than AD patients (*p<0.05),
but were not significantly different than control older
individuals.
TABLE. 99mTc-HMPAO SPECT and MRI Imaging Data
Controls DLB AD Test Statistic
HMPAO-SPECT (n¼ 6) (n¼ 12) (n¼ 9)
ACC 72.3 (10.37) 69.9 (7.6) 69.5 (4.7) F(2, 24)¼ 0.263, p¼ 0.771
MCC 76.8 (7.1) 75.4 (8.1) 75.3 (2.5) F(2, 24)¼ 0.123, p¼ 0.885
PCC 76.2 (5.1) 76.2 (3.4) 72.4 (4.1) F(2, 24)¼ 2.257, p¼ 0.126
Pr/Cu 78.2 (3.9) 73.9 (6.4) 78.7 (4.9) F(2, 24)¼ 2.478, p¼ 0.105
PHG 70.3 (3.3) 71.9 (3.7) 67.4 (6.1) H(2)¼ 4.117, p¼ 0.128
MRI volume mm3 (n¼ 6) (n¼ 10) (n¼ 8)
ACC 1685.7 (829.3) 2170 (411.3) 1665.8 (522.6) F(2, 21)¼ 0.673, p¼ 0.521
MCC 2092.2 (668.3) 1977.1 (648.2) 2158.6 (473) F(2, 21)¼ 0.489, p¼ 0.620
PCC 2907.8 (779.7) 2673.1 (556.5) 1905.4 (368.4) F(2, 21)¼ 6.172, p¼ 0.008; (p5 0.009)a**; (p¼ 0.059)b
99mTc-HMPAO SPECT imaging or 3T structural MRI was performed in dementia with Lewy bodies (DLB), Alzheimer’s disease (AD) patients and controls. Values are
expressed as the mean (6 SD) for the anterior cingulate cortex (ACC), midcingulate cortex (MCC), posterior cingulate cortex (PCC), precuneus/cuneus (Pr/Cu) and parahippocam-
pal gyrus (PHG). No region specific changes were seen between groups for 99mTc-HMPAO SPECT although a significant difference was identified between AD and controls in
PCC volume (Test Statistic: Bold p values indicate significant differences postBonferroni correction; [Control>AD]a; (DLB>AD)b.) Pairwise comparison of cingulate subregions
in DLB showed lower ACC perfusion compared with MCC (**p< 0.01) and PCC (*p< 0.05), and in AD lower ACC perfusion compared with MCC (*p¼ 0.05), but no regional
differences in controls.
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and Pr/Cu perfusion, allows the distinction to be made be-
tween the different disorders (Fig. 3).
The study has a number of strengths, including a clini-
cally well-characterized cohort with neuropathological assess-
ment and antemortem SPECT imaging similar in size to
previously published studies. In contrast to other studies that
used PET ligands for the visualization of tau in AD and DLB
patients (10, 50), we were unable to identify a relationship be-
tween CIS and quantitative tau pathological burden. Using a
combination of biopsy and follow up autopsy investigation, 1
study has demonstrated that plaque and neurofibrillary tangle
density in AD patients changes very little between biopsy and
death (51). This might suggest that other measures such as
synaptic loss and altered metabolism are associated with pa-
tient decline, with neuropathology being an initiator of this
cascade, which once activated is self-sustaining and relatively
independent of amyloid and tau pathology. This may provide
a reason why we did not identify a relationship between CIS
and postmortem quantitative neuropathology. Additionally,
while we detected CIS in our DLB patients using 99mTc-
HMPAO SPECT, FDG-PET imaging has been suggested to
be more sensitive in detecting the CIS (12). Our use of 99mTc-
HMPAO SPECT may not have detected subtle changes in me-
tabolism identifiable through FDG-PET. Furthermore, SPECT
imaging in the current study was performed at different time
points within the disease history, which might influence the
results since previous studies have suggested that CIS is not
present in advanced patients of DLB (49), although we saw no
such correlation in this study. In summary, our results indicate
that neurodegenerative pathology does not correlate with the
CIS and preserved metabolism in the PCC in DLB. Further
investigations are needed to determine whether metabolic def-
icits are attributable to mitochondrial changes, or a loss/dys-
function of synapses in the PCC and if these relate to the CIS.
REFERENCES
1. McKeith IG, Dickson DW, Lowe J. Diagnosis and management of de-
mentia with Lewy bodies: Third report of the DLB Consortium. Neurol-
ogy 2005;65:1863–72
2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management
of dementia with Lewy bodies: Fourth consensus report of the DLB Con-
sortium. Neurology 2017;89:88–100
3. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients
with senile dementia of Lewy body type. BMJ 1992;305:673–8
4. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkin-
son’s disease and parkinsonian dementias. J Clin Psychiatry 2005;66:
633–7
5. O’Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visu-
alized with FP-CIT SPECT in the differential diagnosis of dementia with
Lewy bodies. Arch Neurol 2004;61:919–25
6. Ceravolo R, Volterrani D, Gambaccini G, et al. Dopaminergic degenera-
tion and perfusional impairment in Lewy body dementia and Alzheimer’s
disease. Neurol Sci 2003;24:162–3
7. Yoshita M, Arai H, Arai H, et al. Diagnostic accuracy of 123I-meta-iodo-
benzylguanidine myocardial scintigraphy in dementia with Lewy bodies:
A multicenter study. PLoS One 2015;10:e0120540
8. Colloby SJ, Taylor JP, Firbank MJ, et al. Covariance 99mTc-exameta-
zime SPECT patterns in Alzheimer’s disease and dementia with Lewy
bodies: Utility in differential diagnosis. J Geriatr Psychiatry Neurol
2010;23:54–62
9. Lim SM, Katsifis A, Villemagne VL, et al. The F-18-FDG PET cingulate
island sign and comparison to I-123-beta-CIT SPECT for diagnosis of
dementia with Lewy bodies. J Nucl Med 2009;50:1638–45
10. Graff-Radford J, Murray ME, Lowe VJ, et al. Dementia with Lewy bod-
ies: Basis of cingulate island sign. Neurology 2014;83:801–9
11. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabo-
lism in dementia with Lewy bodies and Alzheimer’s disease. Neurology
1998;51:125–30
12. O’Brien JT, Firbank MJ, Davison C, et al. 18F-FDG PET and perfusion
SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl
Med 2014;55:1959–65
13. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy
bodies. Nature 1997;388:839–40
14. Halliday GM, Holton JL, Revesz T, et al. Neuropathology underlying
clinical variability in patients with synucleinopathies. Acta Neuropathol
2011;122:187–204
15. Colloby SJ, McParland S, O’Brien JT, et al. Neuropathological correlates
of dopaminergic imaging in Alzheimer’s disease and Lewy body demen-
tias. Brain 2012;135:2798–808
16. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation pre-
cedes neuronal loss in the sympathetic ganglia in Lewy body disease.
Acta Neuropathol 2005;109:583–8
17. Imabayashi E, Soma T, Sone D, et al. Validation of the cingulate island
sign with optimized ratios for discriminating dementia with Lewy bodies
from Alzheimer’s disease using brain perfusion SPECT. Ann Nucl Med
2017;31:536–43
18. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-
associated neurofibrillary pathology using paraffin sections and immuno-
cytochemistry. Acta Neuropathol 2006;112:389–404
19. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the hu-
man brain and its relevance for the development of AD. Neurology 2002;
58:1791–800
20. Walker L, McAleese KE, Thomas AJ, et al. Neuropathologically mixed
Alzheimer’s and Lewy body disease: Burden of pathological protein
aggregates differs between clinical phenotypes. Acta Neuropathol 2015;
129:729–48
21. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-
Alzheimer’s Association guidelines for the neuropathologic assessment
of Alzheimer’s disease: A practical approach. Acta Neuropathol 2012;
123:1–11
22. Firbank MJ, Blamire AM, Krishnan MS, et al. Atrophy is associated with
posterior cingulate white matter disruption in dementia with Lewy bodies
and Alzheimer’s disease. Neuroimage 2007;36:1–7
23. Colloby SJ, O’Brien JT, Taylor J-P. Patterns of cerebellar volume loss in
dementia with Lewy bodies and Alzheimer’s disease: A VBM-DARTEL
study. Psychiatry Res 2014;223:187–91
24. Colloby SJ, Fenwick JD, Williams DE, et al. A comparison of Tc-99m-
HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s
disease using statistical parametric mapping. Eur J Nucl Med Mol I
2002;29:615–22
25. Juergen Mai GP. Thomas Voss Atlas of the Human Brain. 3rd ed.
Oxford: Academic Press 2007
26. Patterson L, Rushton SP, Attems J, et al. Degeneration of dopaminergic
circuitry influences depressive symptoms in Lewy body disorders. Brain
Pathol 2018.
27. Gittins R, Harrison PJ. Neuronal density, size and shape in the human an-
terior cingulate cortex: A comparison of Nissl and NeuN staining. Brain
Res Bull 2004;63:155–60
28. Gittins R, Harrison PJ. A quantitative morphometric study of the human
anterior cingulate cortex. Brain Res 2004;1013:212–22
29. Li W, Andreasen NC, Nopoulos P, et al. Automated parcellation of the
brain surface generated from magnetic resonance images. Front Neuroin-
form 2013;7:23
30. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system
for subdividing the human cerebral cortex on MRI scans into gyral based
regions of interest. Neuroimage 2006;31:968–80
31. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Seg-
mentation and surface reconstruction. Neuroimage 1999;9:179–94
32. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex
from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:
11050–5
33. Minoshima S, Foster NL, Sima AA, et al. Alzheimer’s disease versus de-
mentia with Lewy bodies: Cerebral metabolic distinction with autopsy
confirmation. Ann Neurol 2001;50:358–65
J Neuropathol Exp Neurol • Volume 78, Number 8, August 2019 Cingulate Island Sign
723
D
ow
nloaded from
 https://academ
ic.oup.com
/jnen/article-abstract/78/8/717/5528279 by U
niversity of N
ew
castle user on 02 August 2019
34. Higuchi M, Tashiro M, Arai H, et al. Glucose hypometabolism and neu-
ropathological correlates in brains of dementia with Lewy bodies. Exp
Neurol 2000;162:247–56
35. Huang SH, Chang CC, Lui CC, et al. cortical metabolic and nigrostriatal
abnormalities associated with clinical stage-specific dementia with Lewy
bodies. Clin Nucl Med 2015;40:26–31
36. Ishii K, Soma T, Kono AK, et al. Comparison of regional brain volume and
glucose metabolism between patients with mild dementia with Lewy bod-
ies and those with mild Alzheimer’s disease. J Nucl Med 2007;48:704–11
37. Kasanuki K, Iseki E, Fujishiro H, et al. Neuropathological investigation
of the hypometabolic regions on positron emission tomography with
[18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J
Neurol Sci 2012;314:111–9
38. Whitwell JL, Graff-Radford J, Singh TD, et al. 18F-FDG PET in poste-
rior cortical atrophy and dementia with Lewy bodies. J Nucl Med 2017;
58:632–8
39. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and
neuropathologic characteristics of posterior cortical atrophy. Neurology
2004;63:1168–74
40. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically de-
fined subtypes of Alzheimer’s disease with distinct clinical characteris-
tics: A retrospective study. Lancet Neurol 2011;10:785–96
41. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and
functional characterization of Alzheimer’s disease: Evidence for a rela-
tionship between default activity, amyloid, and memory. J Neurosci
2005;25:7709–17
42. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson’s
disease with and without dementia: A comparison with Alzheimer’s dis-
ease, dementia with Lewy bodies and controls. Brain 2004;127:791–800
43. Khundakar AA, Hanson PS, Erskine D, et al. Analysis of primary visual
cortex in dementia with Lewy bodies indicates GABAergic involvement
associated with recurrent complex visual hallucinations. Acta Neuropa-
thol Commun 2016;4:66
44. Ashrafi G, Ryan TA. Glucose metabolism in nerve terminals. Curr Opin
Neurobiol 2017;45:156–61
45. Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alz-
heimer’s disease and Lewy body disease. Biochem Pharmacol 2014;88:
508–16
46. Iizuka T, Kameyama M. Cingulate island sign on FDG-PET is associated
with medial temporal lobe atrophy in dementia with Lewy bodies. Ann
Nucl Med 2016;30:421–9
47. Xie S, Xiao JX, Wang YH, et al. Evaluation of bilateral cingulum with
tractography in patients with Alzheimer’s disease. Neuroreport 2005;16:
1275–8
48. Rose SE, Chen F, Chalk JB, et al. Loss of connectivity in Alzheimer’s
disease: An evaluation of white matter tract integrity with colour coded
MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 2000;69:
528–30
49. Iizuka T, Iizuka R, Kameyama M. Cingulate island sign temporally
changes in dementia with Lewy bodies. Sci Rep 2017;7:14745
50. Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive as-
sessment of Alzheimer’s disease neurofibrillary pathology using 18F-
THK5105 PET. Brain 2014;137:1762–71
51. Mann DM, Marcyniuk B, Yates PO, et al. The progression of the patho-
logical changes of Alzheimer’s disease in frontal and temporal neocortex
examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol
1988;14:177–95
Patterson et al J Neuropathol Exp Neurol • Volume 78, Number 8, August 2019
724
D
ow
nloaded from
 https://academ
ic.oup.com
/jnen/article-abstract/78/8/717/5528279 by U
niversity of N
ew
castle user on 02 August 2019
